 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || izastobart (HIB210) / HIBio
Trial completion: A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers (clinicaltrials.gov) - Jul 1, 2024
P1, N=30, Completed, Sponsor: HI-Bio
Recruiting --> Completed
- || izastobart (HIB210) / HIBio
Enrollment open: A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers (clinicaltrials.gov) - Jul 7, 2023
P1, N=32, Recruiting, Sponsor: HI-Bio
Recruiting --> Completed Not yet recruiting --> Recruiting
- || izastobart (HIB210) / HIBio
New P1 trial: A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers (clinicaltrials.gov) - Jul 3, 2023
P1, N=32, Not yet recruiting, Sponsor: HI-Bio
- | izastobart (HIB210) / HIBio
Trial completion date, Trial primary completion date, Metastases: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Mar 14, 2023
P1, N=25, Recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
Not yet recruiting --> Recruiting Trial completion date: Jan 2023 --> Dec 2025 | Trial primary completion date: Jan 2023 --> Dec 2024
- || izastobart (HIB210) / HIBio
Trial completion, Metastases: Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov) - Dec 12, 2022
P1, N=16, Completed, Sponsor: I-Mab Biopharma Co. Ltd.
Trial completion date: Jan 2023 --> Dec 2025 | Trial primary completion date: Jan 2023 --> Dec 2024 Active, not recruiting --> Completed
- |||||| izastobart (HIB210) / HIBio
New trial, Metastases: Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001 (clinicaltrials.gov) - Aug 23, 2022
P=N/A, N=0, Available, Sponsor: I-Mab Biopharma Co. Ltd.
- || izastobart (HIB210) / HIBio
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov) - Jul 14, 2022
P1, N=16, Active, not recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Sep 2021 --> Oct 2022
- || izastobart (HIB210) / HIBio
Enrollment open, Trial initiation date, Metastases: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 28, 2022
P1, N=25, Recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Sep 2021 --> Oct 2022 Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022
- || izastobart (HIB210) / HIBio
Trial initiation date, Metastases: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 29, 2021
P1, N=25, Not yet recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022 Initiation date: Jul 2021 --> Dec 2021
- || izastobart (HIB210) / HIBio
New P1 trial, Metastases: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 30, 2021
P1, N=25, Not yet recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
- || izastobart (HIB210) / HIBio
Enrollment open, Metastases: Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov) - Feb 8, 2021
P1, N=16, Recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
Initiation date: Jul 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- || izastobart (HIB210) / HIBio
New P1 trial, Metastases: Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov) - Dec 22, 2020
P1, N=16, Not yet recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
- MOR210 / MorphoSys
[VIRTURL] TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy () - Oct 24, 2020 - Abstract #SITC2020SITC_1816;
- MOR210 / MorphoSys
[VIRTUAL] TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy () - Oct 14, 2020 - Abstract #SITC2020SITC_1633;
Conclusions This series of in vitro and in vivo data demonstrate that TJ210 is a differentiated anti-C5aR antibody with unique binding epitope exhibiting superior anti-tumor potential especially in combination with an anti-PD-1 antibody. These data support further clinical studies of TJ210 in patients with solid tumors.
- MOR210 / MorphoSys
[VIRTUAL] TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy () - Oct 14, 2020 - Abstract #SITC2020SITC_898;
Conclusions This series of in vitro and in vivo data demonstrate that TJ210 is a differentiated anti-C5aR antibody with unique binding epitope exhibiting superior anti-tumor potential especially in combination with an anti-PD-1 antibody. These data support further clinical studies of TJ210 in patients with solid tumors.